Immune escape and immune camouflage may reduce the efficacy of RTS,S vaccine in Malawi

Immune escape and immune camouflage may reduce the efficacy of RTS,S vaccine in Malawi

The RTS,S/AS01 malaria vaccine will undergo a pilot vaccination study in sub-Saharan Africa beginning in 2019. RTS,S/AS01 Phase III trials reported an efficacy of 28.3% (children 5–17 months) and 18.3% (infants 6–12 weeks), with substantial variability across study sites. We postulated that the rela...

Full description

Bibliographic Details
Main Authors: Sundos Khan, Matthew Parrillo, Andres H. Gutierrez, Frances E. Terry, Leonard Moise, William D. Martin, Anne S. De Groot
Format: Article
Language:English
Published: Taylor & Francis Group 2020-02-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
malaria
rts
s vaccine
t-cell epitopes
circumsporozoite protein (csp)
immune escape
immune camouflage
immunoinformatics
epimatrix
epicc
janusmatrix
Online Access:http://dx.doi.org/10.1080/21645515.2018.1560772

Internet

http://dx.doi.org/10.1080/21645515.2018.1560772

Similar Items